Concentra Biosciences, LLC sent an unsolicited proposal to acquire Theseus Pharmaceuticals, Inc. (NasdaqGS:THRX) on November 24, 2023. As per consideration, Concentra Biosciences to acquire all outstanding shares of common stock of the Theseus Pharmaceuticals for $3.80 per share in cash, plus a contingent value right.
Theseus Pharmaceuticals, Inc.
Equities
THRX
US88369M1018
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+19.54% | 124B | |
+19.88% | 114B | |
+21.11% | 25.83B | |
-23.54% | 19.42B | |
-18.17% | 16.2B | |
-20.35% | 15.31B | |
+54.45% | 14.32B | |
+8.27% | 14.31B | |
-48.79% | 14.19B |